Report Overview:
CIPN is a common adverse effect of several cancer therapies including taxanes and platinum drugs. Symptoms include decreased sensation and tingling of the hands and feet, severe pain, numbness and muscle weakness, all of which can occur during cancer treatment, and frequently persist after chemotherapy has ended.
There are no approved therapies to combat the debilitating symptoms of CIPN now. Current alternatives include Palliative care using antidepressants, antiepileptic drugs, or opioids, all of which have well known adverse side effects.
The Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size was estimated at USD 1795.15 million in 2023 and is projected to reach USD 2604.66 million by 2029, exhibiting a CAGR of 6.40% during the forecast period.
This report provides a deep insight into the global Chemotherapy Induced Peripheral Neuropathy Treatment market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, Porter?s five forces analysis, value chain analysis, etc.
The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Chemotherapy Induced Peripheral Neuropathy Treatment Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.
In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Chemotherapy Induced Peripheral Neuropathy Treatment market in any manner.
Global Chemotherapy Induced Peripheral Neuropathy Treatment Market: Market Segmentation Analysis
The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.
Key Company
Aptinyx Inc
Asahi Kasei Pharma Corp
Regenacy Pharmaceuticals
MAKScientific LLC
Metys Pharmaceuticals AG
Nemus Bioscience Inc
PledPharma
Sova Pharmaceuticals Inc
DermaXon LLC
Kineta Inc
Krenitsky Pharmaceuticals Inc
PeriphaGen
Apexian Pharma
WinSanTor
Market Segmentation (by Type)
Calcium Channel ?2-delta Ligands
Antidepressants
Opioids
Others
Market Segmentation (by Application)
Platinum Agents
Taxanes
Vinca Alkaloids
Others
Geographic Segmentation
? North America (USA, Canada, Mexico)
? Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
? Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
? South America (Brazil, Argentina, Columbia, Rest of South America)
? The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
Key Benefits of This Market Research:
? Industry drivers, restraints, and opportunities covered in the study
? Neutral perspective on the market performance
? Recent industry trends and developments
? Competitive landscape & strategies of key players
? Potential & niche segments and regions exhibiting promising growth covered
? Historical, current, and projected market size, in terms of value
? In-depth analysis of the Chemotherapy Induced Peripheral Neuropathy Treatment Market
? Overview of the regional outlook of the Chemotherapy Induced Peripheral Neuropathy Treatment Market:
Key Reasons to Buy this Report:
? Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
? This enables you to anticipate market changes to remain ahead of your competitors
? You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
? The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
? Provision of market value (USD Billion) data for each segment and sub-segment
? Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
? Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
? Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
? Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
? The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
? Includes in-depth analysis of the market from various perspectives through Porter?s five forces analysis
? Provides insight into the market through Value Chain
? Market dynamics scenario, along with growth opportunities of the market in the years to come
? 6-month post-sales analyst support
Customization of the Report
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Note: this report may need to undergo a final check or review and this could take about 48 hours.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Chemotherapy Induced Peripheral Neuropathy Treatment Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the Market's Competitive Landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 10 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 11 provides a quantitative analysis of the market size and development potential of each market segment (product type and application) in the next five years.
Chapter 12 is the main points and conclusions of the report.
TABLE OF CONTENTS
Table of Contents
1 Research Methodology and Statistical Scope
1.1 Market Definition and Statistical Scope of Chemotherapy Induced Peripheral Neuropathy Treatment
1.2 Key Market Segments
1.2.1 Chemotherapy Induced Peripheral Neuropathy Treatment Segment by Type
1.2.2 Chemotherapy Induced Peripheral Neuropathy Treatment Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 Chemotherapy Induced Peripheral Neuropathy Treatment Market Overview
2.1 Global Market Overview
2.1.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size (M USD) Estimates and Forecasts (2019-2030)
2.1.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Estimates and Forecasts (2019-2030)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 Chemotherapy Induced Peripheral Neuropathy Treatment Market Competitive Landscape
3.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Manufacturers (2019-2024)
3.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Manufacturers (2019-2024)
3.3 Chemotherapy Induced Peripheral Neuropathy Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global Chemotherapy Induced Peripheral Neuropathy Treatment Average Price by Manufacturers (2019-2024)
3.5 Manufacturers Chemotherapy Induced Peripheral Neuropathy Treatment Sales Sites, Area Served, Product Type
3.6 Chemotherapy Induced Peripheral Neuropathy Treatment Market Competitive Situation and Trends
3.6.1 Chemotherapy Induced Peripheral Neuropathy Treatment Market Concentration Rate
3.6.2 Global 5 and 10 Largest Chemotherapy Induced Peripheral Neuropathy Treatment Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 Chemotherapy Induced Peripheral Neuropathy Treatment Industry Chain Analysis
4.1 Chemotherapy Induced Peripheral Neuropathy Treatment Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 The Development and Dynamics of Chemotherapy Induced Peripheral Neuropathy Treatment Market
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 Chemotherapy Induced Peripheral Neuropathy Treatment Market Segmentation by Type
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Type (2019-2024)
6.3 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size Market Share by Type (2019-2024)
6.4 Global Chemotherapy Induced Peripheral Neuropathy Treatment Price by Type (2019-2024)
7 Chemotherapy Induced Peripheral Neuropathy Treatment Market Segmentation by Application
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Sales by Application (2019-2024)
7.3 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size (M USD) by Application (2019-2024)
7.4 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Growth Rate by Application (2019-2024)
8 Chemotherapy Induced Peripheral Neuropathy Treatment Market Segmentation by Region
8.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Region
8.1.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Region
8.1.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Region
8.2 North America
8.2.1 North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 Key Companies Profile
9.1 Aptinyx Inc
9.1.1 Aptinyx Inc Chemotherapy Induced Peripheral Neuropathy Treatment Basic Information
9.1.2 Aptinyx Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product Overview
9.1.3 Aptinyx Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product Market Performance
9.1.4 Aptinyx Inc Business Overview
9.1.5 Aptinyx Inc Chemotherapy Induced Peripheral Neuropathy Treatment SWOT Analysis
9.1.6 Aptinyx Inc Recent Developments
9.2 Asahi Kasei Pharma Corp
9.2.1 Asahi Kasei Pharma Corp Chemotherapy Induced Peripheral Neuropathy Treatment Basic Information
9.2.2 Asahi Kasei Pharma Corp Chemotherapy Induced Peripheral Neuropathy Treatment Product Overview
9.2.3 Asahi Kasei Pharma Corp Chemotherapy Induced Peripheral Neuropathy Treatment Product Market Performance
9.2.4 Asahi Kasei Pharma Corp Business Overview
9.2.5 Asahi Kasei Pharma Corp Chemotherapy Induced Peripheral Neuropathy Treatment SWOT Analysis
9.2.6 Asahi Kasei Pharma Corp Recent Developments
9.3 Regenacy Pharmaceuticals
9.3.1 Regenacy Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Basic Information
9.3.2 Regenacy Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Product Overview
9.3.3 Regenacy Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Product Market Performance
9.3.4 Regenacy Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment SWOT Analysis
9.3.5 Regenacy Pharmaceuticals Business Overview
9.3.6 Regenacy Pharmaceuticals Recent Developments
9.4 MAKScientific LLC
9.4.1 MAKScientific LLC Chemotherapy Induced Peripheral Neuropathy Treatment Basic Information
9.4.2 MAKScientific LLC Chemotherapy Induced Peripheral Neuropathy Treatment Product Overview
9.4.3 MAKScientific LLC Chemotherapy Induced Peripheral Neuropathy Treatment Product Market Performance
9.4.4 MAKScientific LLC Business Overview
9.4.5 MAKScientific LLC Recent Developments
9.5 Metys Pharmaceuticals AG
9.5.1 Metys Pharmaceuticals AG Chemotherapy Induced Peripheral Neuropathy Treatment Basic Information
9.5.2 Metys Pharmaceuticals AG Chemotherapy Induced Peripheral Neuropathy Treatment Product Overview
9.5.3 Metys Pharmaceuticals AG Chemotherapy Induced Peripheral Neuropathy Treatment Product Market Performance
9.5.4 Metys Pharmaceuticals AG Business Overview
9.5.5 Metys Pharmaceuticals AG Recent Developments
9.6 Nemus Bioscience Inc
9.6.1 Nemus Bioscience Inc Chemotherapy Induced Peripheral Neuropathy Treatment Basic Information
9.6.2 Nemus Bioscience Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product Overview
9.6.3 Nemus Bioscience Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product Market Performance
9.6.4 Nemus Bioscience Inc Business Overview
9.6.5 Nemus Bioscience Inc Recent Developments
9.7 PledPharma
9.7.1 PledPharma Chemotherapy Induced Peripheral Neuropathy Treatment Basic Information
9.7.2 PledPharma Chemotherapy Induced Peripheral Neuropathy Treatment Product Overview
9.7.3 PledPharma Chemotherapy Induced Peripheral Neuropathy Treatment Product Market Performance
9.7.4 PledPharma Business Overview
9.7.5 PledPharma Recent Developments
9.8 Sova Pharmaceuticals Inc
9.8.1 Sova Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Basic Information
9.8.2 Sova Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product Overview
9.8.3 Sova Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product Market Performance
9.8.4 Sova Pharmaceuticals Inc Business Overview
9.8.5 Sova Pharmaceuticals Inc Recent Developments
9.9 DermaXon LLC
9.9.1 DermaXon LLC Chemotherapy Induced Peripheral Neuropathy Treatment Basic Information
9.9.2 DermaXon LLC Chemotherapy Induced Peripheral Neuropathy Treatment Product Overview
9.9.3 DermaXon LLC Chemotherapy Induced Peripheral Neuropathy Treatment Product Market Performance
9.9.4 DermaXon LLC Business Overview
9.9.5 DermaXon LLC Recent Developments
9.10 Kineta Inc
9.10.1 Kineta Inc Chemotherapy Induced Peripheral Neuropathy Treatment Basic Information
9.10.2 Kineta Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product Overview
9.10.3 Kineta Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product Market Performance
9.10.4 Kineta Inc Business Overview
9.10.5 Kineta Inc Recent Developments
9.11 Krenitsky Pharmaceuticals Inc
9.11.1 Krenitsky Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Basic Information
9.11.2 Krenitsky Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product Overview
9.11.3 Krenitsky Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product Market Performance
9.11.4 Krenitsky Pharmaceuticals Inc Business Overview
9.11.5 Krenitsky Pharmaceuticals Inc Recent Developments
9.12 PeriphaGen
9.12.1 PeriphaGen Chemotherapy Induced Peripheral Neuropathy Treatment Basic Information
9.12.2 PeriphaGen Chemotherapy Induced Peripheral Neuropathy Treatment Product Overview
9.12.3 PeriphaGen Chemotherapy Induced Peripheral Neuropathy Treatment Product Market Performance
9.12.4 PeriphaGen Business Overview
9.12.5 PeriphaGen Recent Developments
9.13 Apexian Pharma
9.13.1 Apexian Pharma Chemotherapy Induced Peripheral Neuropathy Treatment Basic Information
9.13.2 Apexian Pharma Chemotherapy Induced Peripheral Neuropathy Treatment Product Overview
9.13.3 Apexian Pharma Chemotherapy Induced Peripheral Neuropathy Treatment Product Market Performance
9.13.4 Apexian Pharma Business Overview
9.13.5 Apexian Pharma Recent Developments
9.14 WinSanTor
9.14.1 WinSanTor Chemotherapy Induced Peripheral Neuropathy Treatment Basic Information
9.14.2 WinSanTor Chemotherapy Induced Peripheral Neuropathy Treatment Product Overview
9.14.3 WinSanTor Chemotherapy Induced Peripheral Neuropathy Treatment Product Market Performance
9.14.4 WinSanTor Business Overview
9.14.5 WinSanTor Recent Developments
10 Chemotherapy Induced Peripheral Neuropathy Treatment Market Forecast by Region
10.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size Forecast
10.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Forecast by Region
10.2.1 North America Market Size Forecast by Country
10.2.2 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Market Size Forecast by Country
10.2.3 Asia Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Market Size Forecast by Region
10.2.4 South America Chemotherapy Induced Peripheral Neuropathy Treatment Market Size Forecast by Country
10.2.5 Middle East and Africa Forecasted Consumption of Chemotherapy Induced Peripheral Neuropathy Treatment by Country
11 Forecast Market by Type and by Application (2025-2030)
11.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Forecast by Type (2025-2030)
11.1.1 Global Forecasted Sales of Chemotherapy Induced Peripheral Neuropathy Treatment by Type (2025-2030)
11.1.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size Forecast by Type (2025-2030)
11.1.3 Global Forecasted Price of Chemotherapy Induced Peripheral Neuropathy Treatment by Type (2025-2030)
11.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Forecast by Application (2025-2030)
11.2.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales (Kilotons) Forecast by Application
11.2.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size (M USD) Forecast by Application (2025-2030)
12 Conclusion and Key Findings
LIST OF TABLES & FIGURES
List of Tables
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Market Size (M USD) Segment Executive Summary
Table 4. Chemotherapy Induced Peripheral Neuropathy Treatment Market Size Comparison by Region (M USD)
Table 5. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales (Kilotons) by Manufacturers (2019-2024)
Table 6. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Manufacturers (2019-2024)
Table 7. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (M USD) by Manufacturers (2019-2024)
Table 8. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Share by Manufacturers (2019-2024)
Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Chemotherapy Induced Peripheral Neuropathy Treatment as of 2022)
Table 10. Global Market Chemotherapy Induced Peripheral Neuropathy Treatment Average Price (USD/Ton) of Key Manufacturers (2019-2024)
Table 11. Manufacturers Chemotherapy Induced Peripheral Neuropathy Treatment Sales Sites and Area Served
Table 12. Manufacturers Chemotherapy Induced Peripheral Neuropathy Treatment Product Type
Table 13. Global Chemotherapy Induced Peripheral Neuropathy Treatment Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Mergers & Acquisitions, Expansion Plans
Table 15. Industry Chain Map of Chemotherapy Induced Peripheral Neuropathy Treatment
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. Chemotherapy Induced Peripheral Neuropathy Treatment Market Challenges
Table 22. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Type (Kilotons)
Table 23. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Type (M USD)
Table 24. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales (Kilotons) by Type (2019-2024)
Table 25. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Type (2019-2024)
Table 26. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size (M USD) by Type (2019-2024)
Table 27. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size Share by Type (2019-2024)
Table 28. Global Chemotherapy Induced Peripheral Neuropathy Treatment Price (USD/Ton) by Type (2019-2024)
Table 29. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales (Kilotons) by Application
Table 30. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Application
Table 31. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Application (2019-2024) & (Kilotons)
Table 32. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Application (2019-2024)
Table 33. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Application (2019-2024) & (M USD)
Table 34. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Share by Application (2019-2024)
Table 35. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Growth Rate by Application (2019-2024)
Table 36. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Region (2019-2024) & (Kilotons)
Table 37. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Region (2019-2024)
Table 38. North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Country (2019-2024) & (Kilotons)
Table 39. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Country (2019-2024) & (Kilotons)
Table 40. Asia Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Region (2019-2024) & (Kilotons)
Table 41. South America Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Country (2019-2024) & (Kilotons)
Table 42. Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Region (2019-2024) & (Kilotons)
Table 43. Aptinyx Inc Chemotherapy Induced Peripheral Neuropathy Treatment Basic Information
Table 44. Aptinyx Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product Overview
Table 45. Aptinyx Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 46. Aptinyx Inc Business Overview
Table 47. Aptinyx Inc Chemotherapy Induced Peripheral Neuropathy Treatment SWOT Analysis
Table 48. Aptinyx Inc Recent Developments
Table 49. Asahi Kasei Pharma Corp Chemotherapy Induced Peripheral Neuropathy Treatment Basic Information
Table 50. Asahi Kasei Pharma Corp Chemotherapy Induced Peripheral Neuropathy Treatment Product Overview
Table 51. Asahi Kasei Pharma Corp Chemotherapy Induced Peripheral Neuropathy Treatment Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 52. Asahi Kasei Pharma Corp Business Overview
Table 53. Asahi Kasei Pharma Corp Chemotherapy Induced Peripheral Neuropathy Treatment SWOT Analysis
Table 54. Asahi Kasei Pharma Corp Recent Developments
Table 55. Regenacy Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Basic Information
Table 56. Regenacy Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Product Overview
Table 57. Regenacy Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 58. Regenacy Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment SWOT Analysis
Table 59. Regenacy Pharmaceuticals Business Overview
Table 60. Regenacy Pharmaceuticals Recent Developments
Table 61. MAKScientific LLC Chemotherapy Induced Peripheral Neuropathy Treatment Basic Information
Table 62. MAKScientific LLC Chemotherapy Induced Peripheral Neuropathy Treatment Product Overview
Table 63. MAKScientific LLC Chemotherapy Induced Peripheral Neuropathy Treatment Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 64. MAKScientific LLC Business Overview
Table 65. MAKScientific LLC Recent Developments
Table 66. Metys Pharmaceuticals AG Chemotherapy Induced Peripheral Neuropathy Treatment Basic Information
Table 67. Metys Pharmaceuticals AG Chemotherapy Induced Peripheral Neuropathy Treatment Product Overview
Table 68. Metys Pharmaceuticals AG Chemotherapy Induced Peripheral Neuropathy Treatment Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 69. Metys Pharmaceuticals AG Business Overview
Table 70. Metys Pharmaceuticals AG Recent Developments
Table 71. Nemus Bioscience Inc Chemotherapy Induced Peripheral Neuropathy Treatment Basic Information
Table 72. Nemus Bioscience Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product Overview
Table 73. Nemus Bioscience Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 74. Nemus Bioscience Inc Business Overview
Table 75. Nemus Bioscience Inc Recent Developments
Table 76. PledPharma Chemotherapy Induced Peripheral Neuropathy Treatment Basic Information
Table 77. PledPharma Chemotherapy Induced Peripheral Neuropathy Treatment Product Overview
Table 78. PledPharma Chemotherapy Induced Peripheral Neuropathy Treatment Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 79. PledPharma Business Overview
Table 80. PledPharma Recent Developments
Table 81. Sova Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Basic Information
Table 82. Sova Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product Overview
Table 83. Sova Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 84. Sova Pharmaceuticals Inc Business Overview
Table 85. Sova Pharmaceuticals Inc Recent Developments
Table 86. DermaXon LLC Chemotherapy Induced Peripheral Neuropathy Treatment Basic Information
Table 87. DermaXon LLC Chemotherapy Induced Peripheral Neuropathy Treatment Product Overview
Table 88. DermaXon LLC Chemotherapy Induced Peripheral Neuropathy Treatment Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 89. DermaXon LLC Business Overview
Table 90. DermaXon LLC Recent Developments
Table 91. Kineta Inc Chemotherapy Induced Peripheral Neuropathy Treatment Basic Information
Table 92. Kineta Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product Overview
Table 93. Kineta Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 94. Kineta Inc Business Overview
Table 95. Kineta Inc Recent Developments
Table 96. Krenitsky Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Basic Information
Table 97. Krenitsky Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product Overview
Table 98. Krenitsky Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 99. Krenitsky Pharmaceuticals Inc Business Overview
Table 100. Krenitsky Pharmaceuticals Inc Recent Developments
Table 101. PeriphaGen Chemotherapy Induced Peripheral Neuropathy Treatment Basic Information
Table 102. PeriphaGen Chemotherapy Induced Peripheral Neuropathy Treatment Product Overview
Table 103. PeriphaGen Chemotherapy Induced Peripheral Neuropathy Treatment Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 104. PeriphaGen Business Overview
Table 105. PeriphaGen Recent Developments
Table 106. Apexian Pharma Chemotherapy Induced Peripheral Neuropathy Treatment Basic Information
Table 107. Apexian Pharma Chemotherapy Induced Peripheral Neuropathy Treatment Product Overview
Table 108. Apexian Pharma Chemotherapy Induced Peripheral Neuropathy Treatment Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 109. Apexian Pharma Business Overview
Table 110. Apexian Pharma Recent Developments
Table 111. WinSanTor Chemotherapy Induced Peripheral Neuropathy Treatment Basic Information
Table 112. WinSanTor Chemotherapy Induced Peripheral Neuropathy Treatment Product Overview
Table 113. WinSanTor Chemotherapy Induced Peripheral Neuropathy Treatment Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 114. WinSanTor Business Overview
Table 115. WinSanTor Recent Developments
Table 116. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Forecast by Region (2025-2030) & (Kilotons)
Table 117. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size Forecast by Region (2025-2030) & (M USD)
Table 118. North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales Forecast by Country (2025-2030) & (Kilotons)
Table 119. North America Chemotherapy Induced Peripheral Neuropathy Treatment Market Size Forecast by Country (2025-2030) & (M USD)
Table 120. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales Forecast by Country (2025-2030) & (Kilotons)
Table 121. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Market Size Forecast by Country (2025-2030) & (M USD)
Table 122. Asia Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Sales Forecast by Region (2025-2030) & (Kilotons)
Table 123. Asia Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Market Size Forecast by Region (2025-2030) & (M USD)
Table 124. South America Chemotherapy Induced Peripheral Neuropathy Treatment Sales Forecast by Country (2025-2030) & (Kilotons)
Table 125. South America Chemotherapy Induced Peripheral Neuropathy Treatment Market Size Forecast by Country (2025-2030) & (M USD)
Table 126. Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Consumption Forecast by Country (2025-2030) & (Units)
Table 127. Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Market Size Forecast by Country (2025-2030) & (M USD)
Table 128. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Forecast by Type (2025-2030) & (Kilotons)
Table 129. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size Forecast by Type (2025-2030) & (M USD)
Table 130. Global Chemotherapy Induced Peripheral Neuropathy Treatment Price Forecast by Type (2025-2030) & (USD/Ton)
Table 131. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales (Kilotons) Forecast by Application (2025-2030)
Table 132. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size Forecast by Application (2025-2030) & (M USD)
List of Figures
Figure 1. Product Picture of Chemotherapy Induced Peripheral Neuropathy Treatment
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size (M USD), 2019-2030
Figure 5. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size (M USD) (2019-2030)
Figure 6. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales (Kilotons) & (2019-2030)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Country (M USD)
Figure 11. Chemotherapy Induced Peripheral Neuropathy Treatment Sales Share by Manufacturers in 2023
Figure 12. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Share by Manufacturers in 2023
Figure 13. Chemotherapy Induced Peripheral Neuropathy Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2023
Figure 14. Global Market Chemotherapy Induced Peripheral Neuropathy Treatment Average Price (USD/Ton) of Key Manufacturers in 2023
Figure 15. The Global 5 and 10 Largest Players: Market Share by Chemotherapy Induced Peripheral Neuropathy Treatment Revenue in 2023
Figure 16. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 17. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Share by Type
Figure 18. Sales Market Share of Chemotherapy Induced Peripheral Neuropathy Treatment by Type (2019-2024)
Figure 19. Sales Market Share of Chemotherapy Induced Peripheral Neuropathy Treatment by Type in 2023
Figure 20. Market Size Share of Chemotherapy Induced Peripheral Neuropathy Treatment by Type (2019-2024)
Figure 21. Market Size Market Share of Chemotherapy Induced Peripheral Neuropathy Treatment by Type in 2023
Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 23. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Share by Application
Figure 24. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Application (2019-2024)
Figure 25. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Application in 2023
Figure 26. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Share by Application (2019-2024)
Figure 27. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Share by Application in 2023
Figure 28. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Growth Rate by Application (2019-2024)
Figure 29. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Region (2019-2024)
Figure 30. North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 31. North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Country in 2023
Figure 32. U.S. Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 33. Canada Chemotherapy Induced Peripheral Neuropathy Treatment Sales (Kilotons) and Growth Rate (2019-2024)
Figure 34. Mexico Chemotherapy Induced Peripheral Neuropathy Treatment Sales (Units) and Growth Rate (2019-2024)
Figure 35. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 36. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Country in 2023
Figure 37. Germany Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 38. France Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 39. U.K. Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 40. Italy Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 41. Russia Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 42. Asia Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Growth Rate (Kilotons)
Figure 43. Asia Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Region in 2023
Figure 44. China Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 45. Japan Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 46. South Korea Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 47. India Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 48. Southeast Asia Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 49. South America Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Growth Rate (Kilotons)
Figure 50. South America Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Country in 2023
Figure 51. Brazil Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 52. Argentina Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 53. Columbia Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 54. Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Growth Rate (Kilotons)
Figure 55. Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Region in 2023
Figure 56. Saudi Arabia Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 57. UAE Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 58. Egypt Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 59. Nigeria Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 60. South Africa Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 61. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Forecast by Volume (2019-2030) & (Kilotons)
Figure 62. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size Forecast by Value (2019-2030) & (M USD)
Figure 63. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share Forecast by Type (2025-2030)
Figure 64. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Share Forecast by Type (2025-2030)
Figure 65. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Forecast by Application (2025-2030)
Figure 66. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Share Forecast by Application (2025-2030)
